Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon J Draper

Showing results (161-170 of 165) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 165 results.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
The New England Journal of Medicine|January 29, 2015
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAKatie Ewer, Tommy Rampling, Navin Venkatraman, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Pageof 17

Showing results (161-170 of 165) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 165 results.
The Lancet. Infectious Diseases|June 16, 2024
Blood-stage malaria vaccine candidate RH5.1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre, phase 1b trialSarah E Silk, Wilmina F Kalinga, Jo Salkeld, et al.
JCI Insight|October 5, 2021
Controlled human malaria infection with a clone of Plasmodium vivax with high-quality genome assemblyAngela M Minassian, Yrene Themistocleous, Sarah E Silk, et al.
JCI Insight|November 3, 2017
Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactionsRuth O Payne, Sarah E Silk, Sean C Elias, et al.
The New England Journal of Medicine|January 29, 2015
A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVAKatie Ewer, Tommy Rampling, Navin Venkatraman, et al.
Med (New York, N.Y.)|July 5, 2021
Reduced blood-stage malaria growth and immune correlates in humans following RH5 vaccinationAngela M Minassian, Sarah E Silk, Jordan R Barrett, et al.
Pageof 17